The Psychedelic Boom: Lilly's Potential Acquisition Sets Stage for Mainstream Breakthrough Eli Lilly's talks to acquire AtaiBeckley, a developer of psychedelic based treatments for mental health conditions, has sent shockwaves through the industry.
Shares of AtaiBeckley skyrocketed 50% premarket on Thursday, with other companies in the sector also seeing significant gains.
This latest development raises questions about the implications of this acquisition and what it means for the growing field of psychedelic research. The surge in interest in psychedelics is not new.